<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02642523</url>
  </required_header>
  <id_info>
    <org_study_id>151768</org_study_id>
    <nct_id>NCT02642523</nct_id>
  </id_info>
  <brief_title>Natriuretic Peptides and Metabolic Risk in Obesity</brief_title>
  <official_title>Natriuretic Peptides and Metabolic Risk in Obesity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators are examining:&#xD;
&#xD;
        1. the relationships of insulin levels and natriuretic peptide hormone levels, and&#xD;
&#xD;
        2. the effects of administering an infusion of natriuretic peptide hormone on the breakdown&#xD;
           of fat&#xD;
&#xD;
      in healthy lean and otherwise healthy obese individuals.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The cardiac natriuretic peptide hormonal system may protect against the development of&#xD;
      cardiometabolic risk. Epidemiologic studies have shown that in relatively healthy individuals&#xD;
      without heart failure, low natriuretic peptide levels are associated with unfavorable&#xD;
      cardiometabolic phenotypes, including higher blood pressure, obesity, higher insulin levels,&#xD;
      and diabetes mellitus. Understanding the mechanisms behind the &quot;natriuretic peptide&#xD;
      deficiency&quot; of obesity would illuminate an important way in which obesity interacts with the&#xD;
      cardiovascular system.&#xD;
&#xD;
      The investigators propose a prospective cross-over design in 40 healthy lean and otherwise&#xD;
      healthy obese individuals. The investigators propose the following specific aims and&#xD;
      hypotheses:&#xD;
&#xD;
      Aim 1: To study the effect of hyperinsulinemia on the response of the natriuretic peptide&#xD;
      system to salt loading.&#xD;
&#xD;
      Hypothesis 1: Hyperinsulinemia will suppress natriuretic peptide levels in both obese and&#xD;
      lean individuals.&#xD;
&#xD;
      Aim 2: To examine the effect of an intravenous infusion of natriuretic peptide on acute&#xD;
      markers of lipolysis.&#xD;
&#xD;
      Hypothesis 2: An intravenous infusion of natriuretic peptide will raise acute markers of&#xD;
      lipolysis in both obese and lean individuals.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Preliminary data run on rat samples showed that this study question and design would not&#xD;
    produce conclusive results. The PI decided not to carry out the study.&#xD;
  </why_stopped>
  <completion_date type="Actual">February 2017</completion_date>
  <primary_completion_date type="Actual">February 2017</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in natriuretic peptide levels</measure>
    <time_frame>4 hours (during 2-hour study infusions and for 2 hours after study infusions)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in glycerol levels</measure>
    <time_frame>1 hour</time_frame>
    <description>Change during 1-hour of low-dose BNP infusion, 1-hour of high-dose BNP infusion, and 1-hour of normal saline infusion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in free fatty acid levels</measure>
    <time_frame>1 hour</time_frame>
    <description>Change during 1-hour of low-dose BNP infusion, 1-hour of high-dose BNP infusion, and 1-hour of normal saline infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in triglyceride levels</measure>
    <time_frame>1 hour</time_frame>
    <description>Change during 1-hour of low-dose BNP infusion, 1-hour of high-dose BNP infusion, and 1-hour of normal saline infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in energy expenditure assessed by indirect calorimetry</measure>
    <time_frame>1 hour</time_frame>
    <description>Change during 1-hour of low-dose BNP infusion, 1-hour of high-dose BNP infusion, and 1-hour of normal saline infusion</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in plasma renin activity</measure>
    <time_frame>4 hours (during 2-hour study infusions and for 2 hours after study infusions)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Change in aldosterone</measure>
    <time_frame>4 hours (during 2-hour study infusions and for 2 hours after study infusions)</time_frame>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Obesity</condition>
  <condition>Hyperinsulinemia</condition>
  <arm_group>
    <arm_group_label>Saline Infusion</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>All subjects will undergo 3 interventions, performed at 3 separate outpatient study visits. The order of the 3 interventions will be randomly assigned. The interventions are: Saline Infusion, Insulin Clamp, and BNP Infusion (Nesiritide).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Insulin Clamp</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects will undergo 3 interventions, performed at 3 separate outpatient study visits. The order of the 3 interventions will be randomly assigned. The interventions are: Saline Infusion, Insulin Clamp, and BNP Infusion (Nesiritide).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BNP Infusion (Nesiritide)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects will undergo 3 interventions, performed at 3 separate outpatient study visits. The order of the 3 interventions will be randomly assigned. The interventions are: Saline Infusion, Insulin Clamp, and BNP Infusion (Nesiritide).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nesiritide</intervention_name>
    <description>Subjects will receive an intravenous infusion of recombinant human b-type natriuretic peptide (BNP) (Nesiritide) over 2 hours at 2 doses: 0.003 ug/kg/min for 1 hour, followed by 0.01 ug/kg/min for 1 hour. Nesiritide (Johnson and Johnson) is FDA-approved for the treatment of heart failure. Study investigators received approval from the FDA for an IND exemption for nesiritide in this study. While receiving the BNP infusion, subjects will also receive an intravenous infusion of normal (0.9%) saline over 2 hours. Subjects will receive a standardized high-salt diet for at least 6 days prior to this study visit.</description>
    <arm_group_label>BNP Infusion (Nesiritide)</arm_group_label>
    <other_name>Recombinant human BNP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin</intervention_name>
    <description>The hyperinsulinemic-euglycemic insulin clamp, which will last between 2-2.5 hours, involves continuous intravenous infusions of human regular insulin and of dextrose solution. Simultaneously, subjects receive an intravenous infusion of normal (0.9%) saline over 2 hours. Subjects will receive a standardized high-salt diet for at least 6 days prior to this study visit.</description>
    <arm_group_label>Insulin Clamp</arm_group_label>
    <other_name>Human Insulin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Subjects will receive an intravenous infusion of normal (0.9%) saline over 2 hours at a rate of 0.25 ml/kg/min. Subjects will receive a standardized high-salt diet for at least 6 days prior to this study visit.</description>
    <arm_group_label>Saline Infusion</arm_group_label>
    <other_name>Normal Saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men and women ages 18-50 years&#xD;
&#xD;
          -  BMI 18 to &lt;25 kg/m2 (lean group, N=20) or BMI 30 to &lt;40 kg/m2 (obese group, N=20)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current use of antihypertensive medications&#xD;
&#xD;
          -  Current use of glucocorticoids, metformin, or any antidiabetes medications&#xD;
&#xD;
          -  Prior or current cardiovascular disease, renal disease, or liver disease&#xD;
&#xD;
          -  Diabetes mellitus (taking insulin, other anti-diabetic agents, or diet-controlled)&#xD;
&#xD;
          -  Atrial fibrillation&#xD;
&#xD;
          -  Bleeding disorder or anemia&#xD;
&#xD;
          -  Elevated LFTs&#xD;
&#xD;
          -  estimuated GFR &lt; 60 ml/min&#xD;
&#xD;
          -  Abnormal sodium or potassium level&#xD;
&#xD;
          -  Positive pregnancy test, women of child-bearing age not practicing birth control,&#xD;
             women who are breastfeeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Katherine N Bachmann, MD</last_name>
    <role>Study Director</role>
    <affiliation>Vanderbilt Diabetes/Endocrinology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thomas J Wang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt Cardiovascular Medicine</affiliation>
  </overall_official>
  <verification_date>October 2017</verification_date>
  <study_first_submitted>November 24, 2015</study_first_submitted>
  <study_first_submitted_qc>December 24, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 30, 2015</study_first_posted>
  <last_update_submitted>October 31, 2017</last_update_submitted>
  <last_update_submitted_qc>October 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University Medical Center</investigator_affiliation>
    <investigator_full_name>Thomas Wang</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>natriuretic peptide</keyword>
  <keyword>insulin</keyword>
  <keyword>lipolysis</keyword>
  <keyword>hormones</keyword>
  <keyword>metabolism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Hyperinsulinism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Natriuretic Peptide, Brain</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

